Canagliflozin as a Longevity Therapy: AgelessRx Trial Findings

Longevity science has a clear goal: stop disease before it starts, instead of treating it after it appears. That matters even if your last lab results looked completely normal. Canagliflozin fits right into that goal. It was first developed for type 2 diabetes, but aging researchers have taken notice. It may activate several metabolic pathways tied to healthy aging, including some of the same ones seen in caloric restriction studies. Our Stanford PhD-led Research Team ran a pilot trial to see if those effects hold in healthy adults without diabetes. The early results are worth sharing.

Key takeaways:

• Canagliflozin is an SGLT2 inhibitor that may mimic caloric restriction by activating AMPK, suppressing mTOR, and nudging autophagy
• In ITP lab studies, Canagliflozin extended median lifespan in male mice by 14%
• Our Stanford PhD-led Research Team designed and led one of the first human trials studying Canagliflozin as a longevity-focused intervention in healthy, non-diabetic adults
• In our pilot trial, Canagliflozin caused measurable glucose excretion in urine, both dosing schedules worked equally well, and no serious side effects were reported

What Is Canagliflozin?

Canagliflozin belongs to a class of medications called SGLT2 inhibitors. It was first developed to manage blood sugar in people with type 2 diabetes. It works by blocking the SGLT2 protein in the kidneys. When this protein is blocked, excess glucose passes into urine instead of being reabsorbed into the bloodstream. Think of the kidneys as a glucose recycling system. Canagliflozin turns that recycling off, so excess glucose leaves the body instead of cycling back into circulation.

This matters for longevity research because it closely mirrors caloric restriction. By lowering blood glucose and insulin levels, Canagliflozin may activate some of the same metabolic pathways tied to longer lifespan in caloric restriction studies. The interesting part is that it may do this without requiring people to change their diet.

Study Design: Our Pilot Trial

The trial enrolled 24 generally healthy adults without diabetes, and was led by our Stanford PhD-led Research Team under Dr. Stefanie Morgan. Participants were split into two groups: one took 100mg of Canagliflozin daily for seven days, the other took 150mg every other day over the same period, for four total doses. This was off-label use in a healthy population outside the medication’s FDA-approved diabetes indication. The trial was designed to measure metabolic response and short-term safety in people without a diagnosed blood sugar condition.

Continuous glucose monitors tracked real-time blood sugar changes throughout the treatment period. Participants also self-reported blood pressure readings, kept dietary journals, and completed surveys. Urine samples were collected over the three days after each participant’s last dose. These measured how long glucose excretion continued after stopping the medication, a detail that matters for understanding how intermittent dosing might work.

What the Trial Found

Our pilot trial included 24 healthy adults. We gave them low-dose Canagliflozin and tracked changes to their blood sugar and urine glucose. The core question was simple: does Canagliflozin cause measurable changes in people without diabetes? Across participants, the answer was yes.

The most notable finding was sugar leaving the body through urine. Some participants eliminated up to 2.1 grams of excess sugar in their urine even 24 to 48 hours after stopping Canagliflozin. Blood sugar levels stayed relatively stable throughout the study, which is an important safety sign. The body appeared to excrete excess glucose while keeping enough in the bloodstream for normal function.

Both dosing schedules worked equally well. Taking 150mg every other day produced the same urine glucose output as taking 100mg daily. That matters for cost, ease of use, and sticking with the regimen over time. It also fits how other longevity-focused medications, such as Rapamycin and Low Dose Naltrexone, are used intermittently to capture benefits while limiting total exposure.

Individual results varied quite a bit. Some participants continued to excrete notable amounts of sugar in their urine for days after stopping the medication. Others showed little to no excretion after the last dose. Food journals did not explain the differences clearly. This suggests that tracking individual response may matter when using Canagliflozin for healthy aging. It is worth noting that this trial had no placebo or control group, so the observed variation in response cannot be fully separated from natural biological fluctuation or other unmeasured factors.

Side effects were minimal at both doses. Reported effects included increased urination, occasional mild dizziness, and increased thirst. These were self-resolving and did not lead to any discontinuation. That is a good sign for anyone considering Canagliflozin for long-term use, especially in healthy people who do not have an active condition.

Blood Sugar as a Driver of Biological Aging

Chronically high blood sugar speeds up aging in a few key ways. First, excess glucose sticks to proteins and DNA in a process called glycation. Over time, this stiffens tissues and disrupts normal cell function. High blood sugar also drives oxidative stress and low-grade inflammation. Both are consistently connected to faster biological aging.

So why does this matter if your blood sugar looks normal? The issue goes deeper than type 2 diabetes risk. Even in healthy adults, blood sugar readings after meals track closely with signs of faster cellular aging. That is why keeping blood sugar stable may be one of the most direct ways to slow biological aging.

This is why SGLT2 inhibitors interest longevity researchers.

The Caloric Restriction Mimetic Hypothesis

What makes this particularly interesting is that the body cannot easily tell the difference between actual caloric restriction and the signal Canagliflozin creates. When the kidneys release glucose into urine instead of reabsorbing it, the body reads this as a mild energy shortage. This activates the same longevity-linked pathways seen in caloric restriction studies. AMPK rises, mTOR activity falls, and cellular cleanup processes like autophagy gets a nudge in the right direction.

What Preclinical and Observational Research Shows

Before Canagliflozin entered human longevity trials, animal and epidemiological research suggested the therapy could do more than manage blood sugar.

Animal Studies Point Toward Lifespan Extension

In mouse studies, Canagliflozin extended median lifespan by roughly 14% in males. Researchers relate part of this to caloric restriction mimicry. The medication causes glucose to pass into urine, which lowers the net calories the body absorbs, without any dietary change required.

Observational Data in Humans

Studies in people with type 2 diabetes show SGLT2 inhibitors are connected to lower rates of death from heart disease and slower kidney decline. This suggests the benefits may go well beyond blood sugar control alone.

What These Findings Mean for Longevity Medicine

Canagliflozin works through some of the same pathways as other well-studied longevity compounds, like Metformin and Rapamycin. Together, these tools may support a broader strategy for healthy aging by targeting multiple pathways at once. That is the direction longevity research is heading.

Why Clinicians Are Paying Attention

For years, researchers have looked for ways to get the metabolic benefits of caloric restriction without requiring major diet changes. Canagliflozin may be one of the more practical options. The early human data gives clinicians something real to work with. For a field that has spent decades mostly in animal studies, that is a meaningful step forward.

Our Commitment to Original Research

We believe the best way to earn your trust is to do the science ourselves. Our Stanford PhD-led Research Team has run 11+ in-house longevity trials, with 9 peer-reviewed publications. This pilot trial is part of that work. It is one of the first studies to look at Canagliflozin through a healthy aging lens, with a focus on prevention over disease treatment. It builds on earlier work like the PEARL Trial. Our team designed and led this trial based on early evidence that SGLT2 inhibitors may extend lifespan through more than just glucose control, including caloric restriction mimicry, lower cellular stress, and better metabolic markers tied to aging.

The immediate goal was to collect early human data on how Canagliflozin affects aging-related markers in healthy people. The bigger goal is to build a solid clinical foundation for larger studies, and to bring well-tested longevity treatments into personalized care sooner.

How This Shapes the Future of Longevity Medicine

The data from this pilot is early, and that is the point. Responsible longevity medicine gets built this way: first you understand the mechanism, then you confirm it in animals, and then you look for real signals in people. That is what this trial did.

Frequently Asked Questions

Note: The above statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.